These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2659235)

  • 1. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.
    Drusano GL; Forrest A; Plaisance KI; Wade JC
    Clin Pharmacol Ther; 1989 Jun; 45(6):635-41. PubMed ID: 2659235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.
    Drusano GL; Plaisance KI; Forrest A; Bustamante C; Devlin A; Standiford HC; Wade JC
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1420-2. PubMed ID: 3479047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.
    Drusano GL
    J Clin Pharmacol; 1991 Oct; 31(10):962-7. PubMed ID: 1761728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.
    Ariano RE; Zelenitsky SA; Nyhlén A; Sitar DS
    J Clin Pharmacol; 2005 Jul; 45(7):832-5. PubMed ID: 15951473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
    Cies JJ; Jain J; Kuti JL
    Pediatr Blood Cancer; 2015 Mar; 62(3):477-82. PubMed ID: 25328131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.
    Del Favero A; Menichetti F; Martino P; Bucaneve G; Micozzi A; Gentile G; Furno P; Russo D; D'Antonio D; Ricci P; Martino B; Mandelli F;
    Clin Infect Dis; 2001 Oct; 33(8):1295-301. PubMed ID: 11565068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
    Janmohamed RM; Leyland MJ; Kelly J; Farrell I
    J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.
    Cometta A; Kern WV; De Bock R; Paesmans M; Vandenbergh M; Crokaert F; Engelhard D; Marchetti O; Akan H; Skoutelis A; Korten V; Vandercam M; Gaya H; Padmos A; Klastersky J; Zinner S; Glauser MP; Calandra T; Viscoli C;
    Clin Infect Dis; 2003 Aug; 37(3):382-9. PubMed ID: 12884163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
    Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
    J Antimicrob Chemother; 2015 Aug; 70(8):2369-75. PubMed ID: 25953805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
    Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
    Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cefmenoxime or piperacillin plus amikacin. A prospective randomized comparison of empiric antibiotic therapy of febrile granulocytopenic cancer patients].
    Sampi K; Kumai R; Maseki N; Sakurai M; Kaneko Y; Hattori M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):674-9. PubMed ID: 3469935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of optimal sampling strategy and adaptive study design.
    Drusano GL; Forrest A; Snyder MJ; Reed MD; Blumer JL
    Clin Pharmacol Ther; 1988 Aug; 44(2):232-8. PubMed ID: 3293877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.